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Over the last 2 decades advances in the diagnosis and management of pituitary diseases 2 
have made it possible to attain an endocrine “cure” in a large proportion of patients.  In 3 
other words, tumors can be excised or controlled with drugs, and mass effect of the 4 
lesion on surrounding structures be solved, and pituitary deficiencies can be substituted 5 
with all relevant hormones.  While this is considered a satisfactory outcome for health 6 
care providers, patients often suffer from an aftermath of prior endocrine dysfunction 7 
exposure, with irreversible effects both physically and psychologically, which have a 8 
great impact on their everyday life. Diagnostic delay, often of several years, adds a 9 
negative impact on health perception.  This affects their social, professional and family 10 
domains and determines their future life.  Understanding that this may occur is 11 
important and health care providers should offer information to prepare the patient for 12 
this difficult journey, especially in the case of acromegaly, Cushing disease or 13 
hypopituitarism. In order to maintain in the long-term a good quality of life, patients 14 
need to adapt to this new situation, something that may be difficult, since they often 15 
cannot continue with all the activities and rhythm they used to do.  Depression is often 16 
the consequence of maladaptation to the new situation, leading to impaired quality of 17 





Quality of life (QoL) does not mean the same for a health care provider (HCP) and 21 
for a patient.  An endocrinologist considers pituitary disease to be controlled if pituitary 22 
hormone function is normal and tumour growth is stable; with current surgery and 23 
medical therapy this is possible nowadays in most patients.    But patients would like to 24 
perform daily activities as they did prior to suffering from pituitary disease, personally 25 
and professionally, without physical or psychological limitations, pain or social or family 26 
problems related to their disease; if this is not the case, the patient will hardly consider 27 
himself "cured" or experience   a good health-related QoL.  They want to feel healthy, 28 
independently of what the hormone or imaging results show.   These subjective feelings 29 
of health perception of the patient, can be measured with Patient Reported Outcome -30 
PRO- questionnaires, and are contemplated by administrators and regulating agencies, 31 
when considering health-related decisions, i.e., authorising reimbursement of new 32 
drugs, or devoting health resources to a particular group of patients. 33 
Questionnaires are more and more frequently used to evaluate QoL and the long-34 
term impact on health perception after suffering pituitary dysfunction [1].  It is now 35 
evident that years after "curing" pituitary dysfunction, patients still suffer from more 36 
cardiovascular, skeletal and neuropsychological morbidity (i.e., worse executive 37 
function, emotional coping, leading to anxiety, depression and psychological distress, as 38 
well as memory and cognition complaints), especially after hypercortisolism of 39 
Cushing’s syndrome (of either pituitary or adrenal origin, or after exogenous treatment 40 
with high doses of glucocorticoids and/or longterm exposure), acromegaly or  41 
hypopituitarism [2-10].  Patients complain of impaired QoL related to dimensions vital 42 
for daily life, but often ignored by clinicians [3].  Common complaints are physical (poor 43 
stamina, body image, and libido) and emotional (slower on the uptake, anxiety or being 44 
depressive) and less frequently social issues, although visual or other problems, which 45 
prevent driving, do have a great negative impact  [1, 2].  46 
Working disability (no paid job, need of sick leave, or not being productive while 47 
at work due to difficulties in concentrating and losing the train of thought) is common in 48 
patients with pituitary tumours; furthermore, patients with a paid job experience a 49 
better QoL than those who are unemployed [11].   Patients with a diagnosis of 50 
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hypopituitarism, acromegaly or Cushing's disease -CD- experience more working 51 
problems than non-functioning pituitary adenomas - NFPA- or Rathke's pouch cysts.  52 
Current use of medical therapy or having undergone radiotherapy impact more 53 
negatively than being controlled after surgery.  Higher education and income levels, as 54 
well as being married or with a stable relationship, are also associated with a greater 55 
probability of being employed (11).  These persistent limitations after pituitary disease 56 
explain the greater probability of early retirement, shorter working hours or the need of 57 
adapting jobs to persistent limitations, in patients with pituitary disease.  Thus, any 58 
initiatives that favour  a better  adaptation to the current situation will be beneficial not 59 
only for the individual patient, but also for society at large.  60 
 61 
 62 
Comparison of the impact of different pituitary diseases on patients’ health 63 
perception 64 
As any other chronic health process, pituitary diseases may affect everyday life.   65 
Features like female gender, older age, hypopituitarism, active disease, depressive 66 
symptoms, negative illness perceptions, prior radiotherapy, tumour recurrence and 67 
frequent check-ups negatively affect perceived health and QoL and are common to all 68 
pituitary diseases.  Other features that affect QoL are specific to acromegaly, CD or 69 
AGHD, situations where QoL is more impaired than in NFPA or prolactinomas [1, 12-17, 70 
20].     71 
The individual patient tends to adapt to perceived limitations, with more or less success.  72 
With a good adaptation, perceived QoL may be quite acceptable despite persistent 73 
morbidity, while maladaptation usually leads to frustration, anxiety or depression and 74 
worse QoL.  Educating patients on the nature and consequences of pituitary diseases by 75 
multidisciplinary teams is helpful to understand the nature and adapt to   limitations 76 
[21].   The patients’ family and social environment can also play a positive role on 77 
patients’ outcome, contributing to accept the new situation, by showing understanding, 78 
comprehension, support, and a positive approach to day-to-day life [22].     79 
In a pilot study carried out when patients attended their outpatient appointment during 80 
2019, they were asked to describe how their pituitary disease had affected their 81 
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everyday life (Santos et al, unpublished results).  Fifty-four patients were interviewed, 82 
14 patients diagnosed of Cushing’s disease, 14 with acromegaly and 14 with a 83 
prolactinoma, and 12 with a non-functioning pituitary adenoma (Table 1).   84 
Patients diagnosed with Cushing’s disease had the greatest impact of the disease on 85 
their life (7.5 out of a maximum of 10), followed by prolactinoma (6.8), acromegaly (6.5) 86 
and non-functioning adenomas (5.8) (Figure 1 A).  In the case of prolactinomas, they 87 
were mostly large macroadenomas, half of which were males with invasive lesions.  In 88 
acromegaly, women declared to have experienced a much greater impact than men (8.9 89 
versus 4.2), while clear gender differences were not observed in other diagnostic groups 90 
(Figure 1 B). 91 
Emotional complaints in these 54 patients globally were more prevalent at diagnosis, 92 
but were still quite prevalent during the interview at follow-up (Table 2).  At diagnosis, 93 
only 18 (33%) recalled to have felt fine, while at follow-up 33 (61%) referred to feel 94 
happy and fine.  Thus, despite improvement, more than half still experienced emotional 95 
discomfort including anxiety, depression, sadness, nervousness, mood swings, worry, 96 
fear, lack of initiative, loneliness or dislike of body image after treatment.   97 
Social issues at diagnosis and during the interview are globally reported in Table 3. At 98 
diagnosis, 70% did not recall any social issues, while 14 (26%) referred not wanting or 99 
experiencing difficulties in going out for different reasons, physical and psychological.  100 
At follow-up, the situation had improved, since 44 patients (81%) referred no problem. 101 
 102 
Promoting patient empowerment by the health care providers 103 
Perception of outcome after treatment of pituitary disease is often overseen or ignored 104 
by health care providers, unless specifically mentioned.  They struggle with QoL issues 105 
not finding any understanding, and feel isolated, lonely and scared, not knowing how to 106 
best manage their perceived declining health into the future.  Listening to the 107 
experiences of “cured” patients (individually or through patient associations) are very 108 
illustrative, and deserve more attention than given up to now.   For example, patients 109 
often state that they were hardly listened to, and since they were endocrinologically 110 
“cured”, their complaints were not considered.  This generates anxiety, feeling 111 
bewildered or a hypochondriac.  If patients are made aware that some of their perceived 112 
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problems may be related to the prior diagnosis, it allows them first to recognize a 113 
problem they are experiencing, with a reason and explanation, which they can therefore 114 
try to tackle.  This gives them peace of mind, energy and hopes that is often perceived as 115 
therapeutic, with a sense of relief, since they find a confirmation that their feelings are 116 
real and not imaginary.  117 
 In words of some cured Cushing disease patients, the discussion on how challenging the 118 
recovery may be after the surgery helps normalize an often very difficult journey. Just 119 
knowing that someone understands the physical and psychological devastating 120 
aftermath of chronic high cortisol levels and what they are going through is very 121 
therapeutic, with a feeling   of being validated and understood. Furthermore, the 122 
devastating changes induced by hypercortisolism on body image are very distressing, as 123 
illustrated by a young graphic designer who drew herself as she recalled she was prior 124 
to treatment, and 2 years later when her adrenal axis was normal (Figure 2). 125 
Education and/or information by devoted and empathic multidisciplinary teams with an 126 
understanding of these persistent issues facilitate an adaptation to these limitations, 127 
making the patients aware that this may occur.   Additionally, understanding and a 128 
positive approach to day-to-day life, comprehension and support from family or friends, 129 
contribute to accept this new situation, affecting positively patients’ health perception 130 
and long-term prognosis.  131 
Patients appreciate that health care providers be patient and encouraging, since they 132 
often cannot grasp all the implications a prior diagnosis of a pituitary disease may have.  133 
It takes time for them to accept the whole situation and adapt to it, especially when they 134 
don’t feel “normal and healthy”.  Most appreciate receiving complete written 135 
information on their diseases and the consequences it may have, although each 136 
individual is unique.  Being kind, empathic and listening to the patients to identify 137 
specific issues which can be dealt with is much appreciated and helps them feel better.  138 
For some, contacting other patients through patient associations, forums, Facebook or 139 





Patient-centred outcome measures including evaluation of QoL, complement 143 
biochemical and radiological workup of pituitary patients.  Health perception is worse in 144 
active disease, especially with hypercortisolism due to Cushing’s disease, acromegaly 145 
and hypopituitarism, and is often still impaired, even in the presence of endocrine 146 
“cure”.   Pre-existing psychopathology like anxiety, depression or an irritable mood 147 
further worsen QoL, while adaptation to the new physical, psychological or social 148 
limitations are associated with better health perception and QoL.  Identification of 149 
persistent anxiety and depression, for example with a simple and easily accessible 150 
questionnaire like HADS (Hospital Anxiety and Depression Scale) can classify those 151 
individuals who may benefit from psychological or psychiatric help to overcome their 152 
problem.  A supportive social or family environment can also be helpful, and can be 153 
favoured by informing and educating the patients and their environment on the nature 154 
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Figure 1 : A) Patient’s subjective impression on the impact of different pituitary 
diseases on everyday life (maximum impact 10, minimum 0). B) Women with 
acromegaly refer a much greater impact of their disease than men, while this 
sexual dimorphism was not observed in other diseases.  
Abbreviations CD: Cushing disease; ACR: acromegaly; PRL: prolactinoma; NF: Non-
functioning adenomas   
 
Fig. 2.  A) Subjective impression of body image while actively cushingoid and B) 2 




Table 1:  Physical impact referred by the patients at diagnosis and during the 
recent interview, in the different pituitary diseases  
Cushing disease (n=14, 3 males; age 27- 75 years; 1 on cortisol-lowering drugs; substitution 
therapy: 3 growth hormone; 8 L-thyroxine; 3 hydrocortisone; 1 testosterone)  
   
At diagnosis During interview: 
Swollen (7) Feeling fine (5) 
Increased weight (5) Feeling tired (6) 
Excessive fatigability (3) Would prefer to be thinner/less swollen (3) 
Body shape (3) Pain (2) 
Hirsutism (3) More visceral fat 
Bruising (3) Heart/walking problems 
Pain (2) Sleeping difficulties 
Sleeping difficulties (2) Curly hair (after radiotherapy) (2) 
Menstrual irregularities (2) Feeling very cold 
 Desire of plastic surgery to recover body image 
       
Acromegaly (n=14, 7 males; age 35- 66 years; 3 on GH-lowering drugs; substitution therapy: 
4 growth hormone; 5 L-thyroxine; 4 hydrocortisone; 3 testosterone) 
At diagnosis During interview: 
Ok, minor changes perceived(3) Feeling fine (3) 
Changes in facial features (3) Pain (7) 
Increase in size of hands and feet (2) Cannot recognize myself in the mirror 
Feeling tired (2) Feeling tired 
Too tall (2) Abdominal discomfort with oral medication 
Pain (2) Desire of plastic surgery to recover body image 
Swollen (2)  
Loss of vision  
 
Prolactinomas (n=14, 8 males; age 27- 61 years; 11 on prolactin-lowering drugs; 
substitution therapy: 1 growth hormone; 4 L-thyroxine; 3 hydrocortisone; 2 testosterone) 
At diagnosis During interview: 
Headache (6) Feeling fine (7) 
Menstrual irregularities (5) Loss of vision (2) 
Loss of vision (5) Feeling tired (2) 
Low sexual desire (4) Desire of plastic surgery to recover body image 
Feeling tired (2) Substitution therapy is imperfect 
Galactorhea (2)  
Increase in breast size (3; 2 ♂)  




Non-functioning adenomas (n=12, 8 males; age 33- 78 years; substitution therapy: 3 growth 
hormone; 4 L-thyroxine; 4 hydrocortisone; 5 testosterone)  
At diagnosis During interview: 
Feeling fine  Feeling fine (6) 
Headache (8) Walking problems (2) 
Loss of vision (5) Low energy 
Dizziness (2) No libido 
Pain (2) Loss of vision 
Vomiting (2) Feeling tired 
Feeling tired   
Nausea  
Impotence, no ejaculation  
 
Table 2: Emotional complaints at diagnosis and during the interview (all 54 patients together, 
Cushing disease, acromegaly, prolactinoma and non-functioning adenoma) 
 
At diagnosis  During interview: 
Feeling fine (18) Feeling fine (30) 
Depression (7) / Sadness (5) Happy (3) 
Fear (5) Do not feel like doing anything (2) 
Mood swings (4) Nervousness / Anxiety (3) 
Irritability (3) / Anger (2) Dislike of my body (3) 
Apathy (2) Sadness /Depression (5) 
Anguish (2) Mood swings (3) 
Nervousness (2) / Anxiety  Worried about medical controls (2) 
Difficulty concentrating  Fear (2) 
Feeling worried Feeling lonely 




Table 3: Social issues at diagnosis and during the interview (all 54 patients together, Cushing 
disease, acromegaly, prolactinoma and non-functioning adenoma) 
 
At diagnosis During interview: 
No impact (38) No problems (44) 
Problems with family/partner (2) Often go out with family and friends (4) 
Did not want to go out (3) Going out less (3) 
Going out less (11) 
  - Only as an obligation (3) 
  - Only when others proposed it (2) 
  - Due to my physical appearance (4) 
  - Due to difficulties walking 
  - Because feeling unwell 
Do not want to go out, it involves too much 
effort (2) 
No sexual desire, leading to problems with 
partner 
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